Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 In Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Principal Investigator

Richard Enelow

Study Number

F18049

Summary

This phase 2 clinical study will be a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.

Phase

Phase II

Contact

Kathy Dickie

Available at the following location(s)

  • Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms

0